Sean Parker, AP

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-pro­file de­but ef­fort in the wave of ac­tiv­i­ty form­ing around cell ther­a­py 2.0. It’s an­oth­er ap­peal­ing Bay Area group that’s at­tract­ed some of the top hands in the busi­ness to a mul­ti-year ef­fort to cre­ate a break­through. And they have $85 mil­lion in hand to make that first big step to the clin­ic.

To­day it’s Ken Drazan and the team at South San Fran­cis­co-based Ar­se­nal­Bio that are com­ing from be­hind the cur­tain for a pub­lic bow, backed by bil­lion­aire Sean Park­er and a col­lec­tion of in­vestors that in­cludes Beth Sei­den­berg’s new ven­ture in­vest­ment op­er­a­tion based in LA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.